SHORTS are not panicking yet true, not just that, they are adding or keeping their shorts in the Money!!!...Obviously, their joy ride is almost going to be nailed hard, they need a "burn their fingers and pockets" lesson that has just began yesterday, continued today, so watch for what is coming soon!!..
Raymond James set a $12.00 target price on Cronos Group (NASDAQ:CRON) in a research report report published on Saturday, December 21st, BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.
Several other equities research analysts have also issued reports on CRON. Piper Jaffray Companies decreased their price target on shares of Cronos Group from $18.00 to $12.00 and set an overweight rating for the company in a research note on Tuesday, October 22nd. Zacks Investment Research lowered shares of Cronos Group from a buy rating to a hold rating in a research note on Wednesday, November 13th. MKM Partners initiated coverage on shares of Cronos Group in a research note on Thursday, September 19th. They set a neutral rating and a $14.00 price target for the company. CIBC restated a buy rating and set a $17.00 price target on shares of Cronos Group in a research note on Wednesday, November 13th. Finally, Stifel Nicolaus upgraded shares of Cronos Group from a hold rating to a buy rating and decreased their price target for the stock from $16.50 to $14.00 in a research note on Friday, October 18th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. Cronos Group currently has a consensus rating of Hold and a consensus price target of $16.49.
Shares of Cronos Group stock traded up $0.38 during mid-day trading on Friday, hitting $7.89. 20,548,203 shares of the stock were exchanged, compared to its average volume of 12,919,822. Cronos Group has a 12 month low of $6.04 and a 12 month high of $25.10. The company has a 50-day simple moving average of $6.95 and a 200 day simple moving average of $10.14. The company has a market capitalization of $2.37 billion, a P/E ratio of -98.63 and a beta of 3.20.
Cronos Group (NASDAQ:CRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. Cronos Group had a net margin of 4,086.41% and a return on equity of 31.88%. The firm had revenue of $10.10 million for the quarter, compared to analysts’ expectations of $10.42 million. On average, research analysts predict that Cronos Group will post -0.13 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Cronos Group by 77.7% in the 2nd quarter. Vanguard Group Inc. now owns 9,068,103 shares of the company’s stock valued at $144,910,000 after buying an additional 3,966,024 shares in the last quarter. ETF Managers Group LLC purchased a new position in Cronos Group in the 2nd quarter valued at approximately $95,437,000. Janus Henderson Group PLC grew its stake in Cronos Group by 4,474.9% in the 2nd quarter. Janus Henderson Group PLC now owns 800,600 shares of the company’s stock valued at $12,871,000 after buying an additional 783,100 shares in the last quarter. Swiss National Bank grew its stake in Cronos Group by 19.1% in the 2nd quarter. Swiss National Bank now owns 693,400 shares of the company’s stock valued at $11,124,000 after buying an additional 111,000 shares in the last quarter. Finally, UBS Asset Management Americas Inc. grew its stake in Cronos Group by 8.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 679,080 shares of the company’s stock valued at $10,918,000 after buying an additional 53,833 shares in the last quarter. Institutional investors and hedge funds own 11.57% of the company’s stock.
About Cronos Group
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations ?MMPR?. The firm typically invests in companies based in Canada.
News 
Market Data 
Discover 
